Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@LegendUSMA Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1920583888587706368.png) @LegendUSMA Legend Biotech Medical Affairs

Legend Biotech Medical Affairs posts on X about events, ash, longterm, stanford university the most. They currently have XXX followers and X posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::1920583888587706368/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1920583888587706368/c:line/m:interactions.svg)

- X Week XXXXX +11,961%
- X Month XXXXX +7,459%
- X Months XXXXX -XX%

### Mentions: X [#](/creator/twitter::1920583888587706368/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1920583888587706368/c:line/m:posts_active.svg)

- X Months XX -XX%

### Followers: XXX [#](/creator/twitter::1920583888587706368/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1920583888587706368/c:line/m:followers.svg)

- X Week XXX +5.60%
- X Month XXX +19%
- X Months XXX +126%

### CreatorRank: undefined [#](/creator/twitter::1920583888587706368/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1920583888587706368/c:line/m:influencer_rank.svg)

### Social Influence

**Social topic influence**
[events](/topic/events) 28.57%, [ash](/topic/ash) 14.29%, [longterm](/topic/longterm) 14.29%, [stanford university](/topic/stanford-university) 14.29%, [thank you](/topic/thank-you) XXXXX%

**Top accounts mentioned or mentioned by**
[@endmyeloma](/creator/undefined) [@bhemato](/creator/undefined) [@surbhisidanamd](/creator/undefined)
### Top Social Posts
Top posts by engagements in the last XX hours

"At the 2025 ASH Annual Meeting our focus remains clear: driving innovation that puts patients at the center. Excited to collaborate and share progress with the hematology community For more link here: #mmsm #lymsm"  
[X Link](https://x.com/LegendUSMA/status/1996600574091886783)  2025-12-04T15:20Z XXX followers, XXX engagements


"Join Dr. Luciano Costa (@End_myeloma) for an oral presentation at #ASH25 to learn about the long-term progression-free survival benefit with a BCMA-directed #CART therapy in standard-risk relapsed / refractory multiple myeloma. For more link here: #mmsm"  
[X Link](https://x.com/LegendUSMA/status/1997301139071771079)  2025-12-06T13:44Z XXX followers, 1015 engagements


"Dr. Binod Dhakal (@bhemato) presents at #ASH25 on effectiveness of bridging therapy corresponds to improved outcomes in the Phase X CARTITUDE-4 study of patients with relapsed lenalidomide-refractory multiple myeloma. For more link here: #mmsm #CART"  
[X Link](https://x.com/LegendUSMA/status/1997370555536683319)  2025-12-06T18:20Z XXX followers, XXX engagements


"Robert Bowden (Johnson & Johnson) presents at #ASH25 on improved manufacturing outcomes with BCMA-directed #CART therapy in earlier lines of therapy. For more link here: #mmsm"  
[X Link](https://x.com/LegendUSMA/status/1997380930286072158)  2025-12-06T19:01Z XXX followers, XXX engagements


"At #ASH25 Dr. Doris Hansen presents real-world incidence and management of non-ICANS neurological events following a BCMA-directed #CART cell therapy in multiple myeloma. Link: #mmsm"  
[X Link](https://x.com/LegendUSMA/status/1997696306278797566)  2025-12-07T15:54Z XXX followers, XXX engagements


"Dr. Surbhi Sidana (@SurbhiSidanaMD) of Stanford University presents a quality-adjusted survival analysis of neurological events with a BCMA-directed #CART therapy vs standard of care in multiple myeloma patients in the CARTITUDE-4 trial. Link: #mmsm"  
[X Link](https://x.com/LegendUSMA/status/1998021147917791403)  2025-12-08T13:25Z XXX followers, XXX engagements


"A heartfelt thank you to all who joined us at #ASH25 attended sessions and visited our posters. Together were pushing boundaries in #CART therapy and accelerating better outcomes for patients with #mmsm and #lymsm"  
[X Link](https://x.com/LegendUSMA/status/1998498870704361546)  2025-12-09T21:03Z XXX followers, XX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@LegendUSMA Avatar @LegendUSMA Legend Biotech Medical Affairs

Legend Biotech Medical Affairs posts on X about events, ash, longterm, stanford university the most. They currently have XXX followers and X posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

Engagements Line Chart

  • X Week XXXXX +11,961%
  • X Month XXXXX +7,459%
  • X Months XXXXX -XX%

Mentions: X #

Mentions Line Chart

  • X Months XX -XX%

Followers: XXX #

Followers Line Chart

  • X Week XXX +5.60%
  • X Month XXX +19%
  • X Months XXX +126%

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence

Social topic influence events 28.57%, ash 14.29%, longterm 14.29%, stanford university 14.29%, thank you XXXXX%

Top accounts mentioned or mentioned by @endmyeloma @bhemato @surbhisidanamd

Top Social Posts

Top posts by engagements in the last XX hours

"At the 2025 ASH Annual Meeting our focus remains clear: driving innovation that puts patients at the center. Excited to collaborate and share progress with the hematology community For more link here: #mmsm #lymsm"
X Link 2025-12-04T15:20Z XXX followers, XXX engagements

"Join Dr. Luciano Costa (@End_myeloma) for an oral presentation at #ASH25 to learn about the long-term progression-free survival benefit with a BCMA-directed #CART therapy in standard-risk relapsed / refractory multiple myeloma. For more link here: #mmsm"
X Link 2025-12-06T13:44Z XXX followers, 1015 engagements

"Dr. Binod Dhakal (@bhemato) presents at #ASH25 on effectiveness of bridging therapy corresponds to improved outcomes in the Phase X CARTITUDE-4 study of patients with relapsed lenalidomide-refractory multiple myeloma. For more link here: #mmsm #CART"
X Link 2025-12-06T18:20Z XXX followers, XXX engagements

"Robert Bowden (Johnson & Johnson) presents at #ASH25 on improved manufacturing outcomes with BCMA-directed #CART therapy in earlier lines of therapy. For more link here: #mmsm"
X Link 2025-12-06T19:01Z XXX followers, XXX engagements

"At #ASH25 Dr. Doris Hansen presents real-world incidence and management of non-ICANS neurological events following a BCMA-directed #CART cell therapy in multiple myeloma. Link: #mmsm"
X Link 2025-12-07T15:54Z XXX followers, XXX engagements

"Dr. Surbhi Sidana (@SurbhiSidanaMD) of Stanford University presents a quality-adjusted survival analysis of neurological events with a BCMA-directed #CART therapy vs standard of care in multiple myeloma patients in the CARTITUDE-4 trial. Link: #mmsm"
X Link 2025-12-08T13:25Z XXX followers, XXX engagements

"A heartfelt thank you to all who joined us at #ASH25 attended sessions and visited our posters. Together were pushing boundaries in #CART therapy and accelerating better outcomes for patients with #mmsm and #lymsm"
X Link 2025-12-09T21:03Z XXX followers, XX engagements

@LegendUSMA
/creator/twitter::LegendUSMA